Research and Development Expense (TTM) Chart

Historical Research and Development Expense (TTM) Data

View and export this data back to 2013. Start Trial.
Date Value
September 30, 2026 87.29M
June 30, 2026 88.36M
March 31, 2026 90.91M
December 31, 2025 94.93M
September 30, 2025 101.36M
June 30, 2025 108.79M
March 31, 2025 114.52M
December 31, 2024 116.04M
September 30, 2024 114.17M
June 30, 2024 113.67M
March 31, 2024 120.19M
December 31, 2023 154.31M
September 30, 2023 209.73M
June 30, 2023 256.82M
March 31, 2023 298.76M
December 31, 2022 306.70M
September 30, 2022 291.66M
June 30, 2022 266.64M
March 31, 2022 235.15M
December 31, 2021 209.67M
September 30, 2021 180.48M
June 30, 2021 158.79M
March 31, 2021 137.86M
December 31, 2020 122.54M
September 30, 2020 109.00M
Date Value
June 30, 2020 101.70M
March 31, 2020 97.40M
December 31, 2019 86.12M
September 30, 2019 75.30M
June 30, 2019 66.01M
March 31, 2019 60.92M
December 31, 2018 54.82M
September 30, 2018 50.65M
June 30, 2018 45.66M
March 31, 2018 36.82M
December 31, 2017 33.39M
September 30, 2017 29.82M
June 30, 2017 28.07M
March 31, 2017 26.92M
December 31, 2016 25.57M
September 30, 2016 24.77M
June 30, 2016 23.00M
March 31, 2016 21.14M
December 31, 2015 19.30M
September 30, 2015 17.82M
June 30, 2015 16.97M
March 31, 2015 16.11M
December 31, 2014 15.94M
September 30, 2014 15.10M
June 30, 2014 14.51M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (TTM) Range, Past 5 Years

View Research and Development Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (TTM) Benchmarks

View Research and Development Expense (TTM) Benchmarks
Start Trial
AVITA Medical, Inc. 21.10M
Agenus, Inc. 45.74M
Amgen, Inc. 7.849B
Anika Therapeutics, Inc. 28.40M
BioCryst Pharmaceuticals, Inc. 209.16M